NIAID has a comprehensive research infrastructure with extensive resources that support all levels of biodefense and emerging infectious diseases research and pursuit of multiple broad-spectrum concepts. This infrastructure includes:
In 2014, NIAID established the CETR program focused on countering threats from emerging and re-emerging infectious diseases. The Centers support multifaceted research and development activities that promote scientific discovery and the translational research to create the next generation of therapeutics, vaccines, and diagnostics. The CETR program builds upon the accomplishments of NIAID's Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) program and other NIAID-supported programs.
These clinical sites, located at eight universities nationwide, allow for extensive clinical trials capacity and expertise. They played a key role in testing the vaccine for the 2009 H1N1 influenza pandemic.
These five centers, located at universities in the United States, conduct prospective international or domestic animal influenza surveillance to rapidly detect and characterize influenza viruses with pandemic potential. The centers also conduct research to enhance understanding of the molecular, ecological, or environmental factors that influence the pathogenesis, transmission, and evolution of influenza viruses; and that characterize the protective immune response.For more information on NIAID resources and infrastructure, please see:
Last Updated March 18, 2015
Last Reviewed October 18, 2011